What is the 13F Pro Quality Score for MTNB?

13F Pro ranks Matinas BioPharma Holdings, Inc. (MTNB) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MTNB's current score at https://13fpro.ai/research/MTNB (free sign-up required for the full ranking).

Which hedge funds own the most MTNB stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of MTNB include GEODE CAPITAL MANAGEMENT,, CITADEL ADVISORS, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/MTNB as soon as new 13F filings post.

Where does 13F Pro source MTNB data?

All Matinas BioPharma Holdings, Inc. fundamentals and ownership data come directly from SEC EDGAR. Matinas BioPharma Holdings, Inc. files with the SEC under CIK 1582554. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MTNB in?

Matinas BioPharma Holdings, Inc. (MTNB) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MTNB research updated on 13F Pro?

MTNB's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Matinas BioPharma Holdings, Inc.(MTNB)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1582554 MTNB stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $3.2M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

MTNB Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Matinas BioPharma Holdings, Inc. (MTNB), a Healthcare sector company. MTNB is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $3.2m in revenue. Based on the latest XBRL financial filings (Q1 2026), Matinas BioPharma Holdings, Inc. reports net income of $-1.9M, free cash flow of $-1.6M. Top institutional holders of MTNB by reported 13-F value include GEODE CAPITAL MANAGEMENT,, CITADEL ADVISORS, BlackRock,, based on the most recent SEC filings. MTNB trades on the NYSE exchange and files with the SEC under CIK 1582554. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MTNB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Matinas BioPharma Holdings, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-1.9M

Free Cash Flow

Q1 2026

$-1.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY18 $119.8KFY23 $1.1MFY24 —FY25 —

Net Income

+57.3% YoY

$-10.3MFY 2025

FY18 $-14.1MFY23 $-22.9MFY24 $-24.3MFY25 $-10.3M

Operating Income

+71.7% YoY

$-7.0MFY 2025

FY18 $-14.6MFY23 $-23.8MFY24 $-24.6MFY25 $-7.0M

EPS (Diluted)

+59.8% YoY

$-2.00FY 2025

FY18 —FY23 $-5.28FY24 $-4.98FY25 $-2.00

Total Assets

-43.0% YoY

$7.2MFY 2025

FY18 $19.9MFY23 $25.1MFY24 $12.6MFY25 $7.2M

Op. Cash Flow

+55.9% YoY

$-7.0MFY 2025

FY18 $-10.3MFY23 $-15.3MFY24 $-15.9MFY25 $-7.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2018	FY 2017	FY 2016
Revenue	—	—	$1.1M +815.2%	$119.8K -20.0%	$149.7K	$0.00
Net Income	$-10.3M +57.3%	$-24.3M -5.7%	$-22.9M -62.9%	$-14.1M +9.1%	$-15.5M -103.8%	$-7.6M
Operating Income	$-7.0M +71.7%	$-24.6M -3.5%	$-23.8M -62.3%	$-14.6M +11.2%	$-16.5M -99.9%	$-8.3M
EPS (Diluted)	$-2.00 +59.8%	$-4.98 +5.7%	$-5.28	—	—	—
Total Assets	$7.2M -43.0%	$12.6M -49.6%	$25.1M +25.9%	$19.9M +38.3%	$14.4M +46.9%	$9.8M
Operating Cash Flow	$-7.0M +55.9%	$-15.9M -4.0%	$-15.3M -48.0%	$-10.3M +9.9%	$-11.5M -87.3%	$-6.1M

AI Insight: MTNB Financial Trends

Matinas BioPharma remains pre-revenue with equity eroding to $3M in Q1 2026, raising acute going-concern risk.

• Equity has collapsed from $19M in Q2 2024 to $3M in Q1 2026, a deterioration of $16M over eight quarters.

• Operating cash burn moderated from -$4M per quarter in Q3–Q4 2024 to -$1M to -$2M range through 2025–Q1 2026.

• The company has generated zero revenue across all reported periods, with no sign of commercial inflection.

⚠ Equity of just $3M in Q1 2026 against ongoing quarterly cash burn signals potential insolvency without new financing.

⚠ No debt reported, but absence of revenue and thin equity make future capital raises highly likely and dilutive.

AI Insight: MTNB Ratio Trends

Data is too sparse to draw reliable margin or return trends; only partial ROE and ROA figures are available across a pre-revenue biotech.

• ROE improved modestly from -119.8% in Q2 2024 to -94.9% in Q3 2025, suggesting slower equity erosion.

• ROA improved from -93.9% in Q2 2024 to -55.0% in Q1 2025, then deteriorated to -63.2% by Q3 2025.

• ROE spiked sharply to -158.3% in Q4 2025, reversing the prior improvement trend abruptly.

⚠ Q4 2025 ROE collapse to -158.3% — worst reading in the dataset — warrants scrutiny of that quarter's cash burn or equity dilution.

⚠ OpMargin, NPM, D/E, and ROIC are almost entirely absent, making comprehensive financial health assessment impossible.

Get alerted when MTNB's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Matinas BioPharma Holdings, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MTNB

GEODE CAPITAL MANAGEMENT, LLC
$32.6K65,170 sh
CITADEL ADVISORS LLC
$25.8K51,698 sh
BlackRock, Inc.
$24.8K49,650 sh
VANGUARD CAPITAL MANAGEMENT LLC
$20.1K40,110 sh
Holos Integrated Wealth LLC
$16.3K32,480 sh
RENAISSANCE TECHNOLOGIES LLC
$14.3K28,570 sh
XTX Topco Ltd
$10.4K20,706 sh
VANGUARD FIDUCIARY TRUST CO
$9.1K18,277 sh
STATE STREET CORP
$7.7K15,322 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$7.2K14,328 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$32.6K	65,170
CITADEL ADVISORS LLC	$25.8K	51,698
BlackRock, Inc.	$24.8K	49,650
VANGUARD CAPITAL MANAGEMENT LLC	$20.1K	40,110
Holos Integrated Wealth LLC	$16.3K	32,480
RENAISSANCE TECHNOLOGIES LLC	$14.3K	28,570
XTX Topco Ltd	$10.4K	20,706
VANGUARD FIDUCIARY TRUST CO	$9.1K	18,277
STATE STREET CORP	$7.7K	15,322
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$7.2K	14,328

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MTNB on your watchlist

Track score changes the day Matinas BioPharma Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MTNB a good stock to buy?

13F Pro's AI-powered analysis of Matinas BioPharma Holdings, Inc. (MTNB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MTNB are available on the MTNB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MTNB?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MTNB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Matinas BioPharma Holdings, Inc.'s investment landscape.